VBS.AU Vectus Biosystems Ltd
- Market cap
- AUD 4.66M
- P/E
- 2.5x
- P/B
- 2.01x
- ROE
- 67.2%
- Dividend yield
- -
- Fundamental score
- 2.3/5
Ratios use the latest price and the fiscal year ending Jun 2026.
Is VBS.AU undervalued?
Graham numberVBS.AU trades 52.7% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Vectus Biosystems Ltd fundamental analysis
11 of 22 checks passedROE 2/2
High return on equity (67.2%), above 20%.
ROA 1/1
Return on assets (40.8%) is above the industry median (-51.4%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 1/1
Last year's EPS growth (184.3%) is above the industry median (-5.3%).
Revenue Growth 0/2
Revenue did not grow over the past 3 years or is not reported.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (23.6%), 40% or less.
Debt Trend 0/1
Debt to equity history is shorter than 5 years.
Debt Coverage 0/1
Operating cash flow does not cover 20% of total debt.
Interest Coverage 0/1
EBIT is negative, against interest expense, below 5x.
PE vs Market 1/1
PE (2.5x) is below the market median (15.0x).
PE vs Industry 1/1
PE (2.5x) is below the industry median (16.3x).
PBV 1/1
Price to book (2.0x) is below the industry median (4.4x).
Graham Number 1/1
The price is below the Graham number (PE x PB = 5.0, limit 22.5).
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Vectus Biosystems Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Vectus Biosystems Ltd
Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops a pipeline of antifibrotic assets targeting cardiovascular, renal and liver fibrosis to address diseases driven by pathological tissue scarring. Its lead compound is VB0004, currently under phase Ib clinical human trial, which targets the prevention and reversal of fibrosis in the lungs, heart, and kidneys. The company was incorporated in 2005 and is based …
Full company profileVectus Biosystems Ltd financial statements
Vectus Biosystems Ltd annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 49.3K | 1.83K | 220.00 | 51.2K | 180.00 | 1.30M | 1.35M | 1.14M | 478K | - |
| Gross Profit | 49.3K | -18.3K | -22.4K | 31.7K | 1.02M | 1.28M | 1.31M | 1.14M | 478K | -4.60K |
| Operating Income | -4.82M | -3.99M | -2.37M | -2.71M | -3.80M | -4.60M | -4.60M | -2.27M | -1.69M | -1.37M |
| EBITDA | -4.79M | -3.97M | -2.35M | -2.64M | -3.71M | -3.28M | -3.19M | -2.27M | -1.69M | -1.36M |
| Net Income | -3.79M | -2.59M | -1.60M | -3.00M | -3.86M | -3.99M | -3.45M | -2.34M | -1.78M | 1.56M |
| EPS | -0.16 | -0.11 | -0.07 | -0.13 | -0.14 | -0.12 | -0.07 | -0.04 | -0.03 | 0.03 |
| Balance Sheet | ||||||||||
| Total Assets | 721K | 196K | 194K | 3.00M | 6.98M | 3.94M | 4.63M | 2.03M | 783K | 3.82M |
| Total Liabilities | 604K | 2.45M | 3.92M | 9.71M | 9.88M | 8.36M | 1.11M | 539K | 1.04M | 1.50M |
| Shareholders' Equity | 117K | -2.26M | -3.73M | -6.71M | -2.90M | -4.42M | 3.52M | 1.49M | -257K | 2.32M |
| Cash & Short-term Investments | 517K | 41.8K | 43.2K | 2.72M | 5.78M | 1.28M | 2.95M | 809K | 251K | 3.52M |
| Total Debt | - | 912K | 1.97M | 8.28M | 8.68M | 6.90M | 70.2K | 28.9K | 200K | 547K |
| Cash Flow | ||||||||||
| Operating Cash Flow | -3.89M | -1.39M | -1.04M | -3.00M | -3.26M | -4.44M | -2.35M | -2.03M | -830K | -573K |
| Capital Expenditure | 39.3K | 0.00 | 21.0K | 21.0K | 2.00 | 21.0K | 17.1K | 67.9K | 2.00 | 5.00 |
| Free Cash Flow | -3.93M | -1.39M | -1.04M | -3.00M | -3.26M | -4.46M | -2.37M | -2.10M | -830K | -573K |
| Ratios | ||||||||||
| ROE | -3,255.1% | - | - | - | - | - | -97.9% | -157.3% | - | 67.2% |
| ROA | -526.6% | -1,318.1% | -822.4% | -99.9% | -55.3% | -101.5% | -74.5% | -115.4% | -227.1% | 40.8% |
| Net Profit Margin | -7,690.5% | -141,614.4% | -725,581.8% | -5,853.3% | -2,145,135.6% | -307.2% | -254.6% | -205.3% | -371.7% | - |
| Debt to Equity | - | - | - | - | - | - | 0.02x | 0.02x | - | 0.24x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Vectus Biosystems Ltd dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | - | - | - |
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | AUD 4.03M | 0.08 | - |
| 2022 | AUD 4.10M | 0.12 | - |
| 2021 | AUD 6.26M | 0.22 | - |
| 2020 | AUD 6.89M | 0.29 | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Vectus Biosystems Ltd
- Insiders 50.90%
- Institutions 6.45%
- Public & others 42.65%
- Shares outstanding 62.2M
- Free float 23.4M
Vectus Biosystems Ltd company profile
- Company name
- Vectus Biosystems Ltd
- Ticker
- VBS.AU
- ISIN
- AU000000VBS9
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- June
- Address
- 26-34 Dunning Avenue, Rosebery, NSW, Australia, 2018
- Phone
- 61 2 8344 1300
- Website
- vectusbiosystems.com.au
About Vectus Biosystems Ltd
Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops a pipeline of antifibrotic assets targeting cardiovascular, renal and liver fibrosis to address diseases driven by pathological tissue scarring. Its lead compound is VB0004, currently under phase Ib clinical human trial, which targets the prevention and reversal of fibrosis in the lungs, heart, and kidneys. The company was incorporated in 2005 and is based in Rosebery, Australia.
Vectus Biosystems Ltd management
3- Dr. Tara SperanzaCEO & CTO
- Mr. Robert John Waring BEc, CA, FAICD, FCIS, FFinCompany Secretary
- Prof. Graham Jon MacDonald AM, BS, BSc (Med), FANZCC, FRACP, FRCP, M.D.Consultant